Combination of EGFR-specific TKIs or cetuximab and the c-MET inhibitor su11274.

<p><b>Panel A</b>: proliferation of cells following single or combined TKI treatment. Cell lines H358 (white), H1650 (grey) and H1975 (black) were cultured in RPMI containing 10% FBS and 1 µM su11274, gefitinib, erlotinib, afatinib or cetuximab, and their combinations. The proliferation was assayed 72 h post treatment using a colorimetric MTS assay. <b>Panel B</b>: caspase −3/7 induction by single or combined TKI treatment. * <i>P</i><0.05 and ** <i>P</i><0.01 compared to both single treatment.